@article{fdi:010072045,
  title = {{E}fficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated {P}lasmodium falciparum malaria in {M}aradi, {N}iger},
  author = {{G}randesso, {F}. and {G}uindo, {O}. and {M}esse, {L}. {W}. and {M}akarimi, {R}. and {T}raore, {A}. and {D}ama, {S}. and {L}aminou, {I}. {M}. and {R}igal, {J}. and de {S}met, {M}. and {O}ukem-{B}oyer, {O}. {O}. {M}. and {D}oumbo, {O}. {K}. and {D}jimde, {A}. and {E}tard, {J}ean-{F}ran{\c{c}}ois},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {M}alaria endemic countries need to assess efficacy of anti-malarial treatments on a regular basis. {M}oreover, resistance to artemisinin that is established across mainland {S}outh-{E}ast {A}sia represents today a major threat to global health. {M}onitoring the efficacy of artemisinin-based combination therapies is of paramount importance to detect as early as possible the emergence of resistance in {A}frican countries that toll the highest burden of malaria morbidity and mortality. {M}ethods: {A} {WHO} standard protocol was used to assess efficacy of the combinations artesunate-amodiaquine ({AS}-{AQ} {W}inthrop ({R})), dihydroartemisinin-piperaquine ({DHA}-{PPQ}, {E}urartesim ({R})) and artemether-lumefantrine ({AM}-{LM}, {C}oartem ({R})) taken under supervision and respecting pharmaceutical recommendations. {T}he study enrolled for each treatment arm 212 children aged 6-59 months living in {M}aradi ({N}iger) and suffering with uncomplicated falciparum malaria. {T}he {K}aplan-{M}eier 42-day {PCR}-adjusted cure rate was the primary outcome. {A} standardized parasite clearance estimator was used to assess delayed parasite clearance as surrogate maker of suspected artemisinin resistance. {R}esults: {N}o early treatment failures were found in any of the study treatment arms. {T}he day-42 {PCR}-adjusted cure rate estimates were 99.5, 98.4 and 99.0% in the {AS}-{AQ}, {DHA}-{PPQ} and {AM}-{LM} arms, respectively. {T}he reinfection rate (expressed also as {K}aplan-{M}eier estimates) was higher in the {AM}-{LM} arm (32.4%) than in the {AS}-{AQ} (13.8%) and the {DHA}-{PPQ} arm (24.9%). {T}he parasite clearance rate constant was 0.27, 0.26 and 0.25 per hour for {AS}-{AQ}, {DHA}-{PPQ} and {AM}-{LM}, respectively. {C}onclusions: {A}ll the three treatments evaluated largely meet {WHO} criteria (at least 95% efficacy). {AS}-{AQ} and {AL}-{LM} may continue to be used and {DHA}-{PPQ} may be also recommended as first-line treatment for uncomplicated falciparum malaria in {M}aradi. {T}he parasite clearance rate were consistent with reference values indicating no suspected artemisinin resistance. {N}evertheless, the monitoring of anti-malarial drug efficacy should continue.},
  keywords = {{M}alaria ; {E}fficacy ; {A}ntimalarial ; {A}rtemisinin ; {R}esistance ; {P}arasite ; clearance ; {N}iger ; {NIGER}},
  booktitle = {},
  journal = {{M}alaria {J}ournal},
  volume = {17},
  numero = {},
  pages = {52},
  ISSN = {1475-2875},
  year = {2018},
  DOI = {10.1186/s12936-018-2200-1},
  URL = {https://www.documentation.ird.fr/hor/fdi:010072045},
}